PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
äŒæ¥ã³ãŒãPRCT
äŒç€ŸåProcept Biorobotics Corp
äžå Žæ¥Sep 15, 2021
æé«çµå¶è²¬ä»»è
ãCEOãWood (Larry L)
åŸæ¥å¡æ°756
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Sep 15
æ¬ç€Ÿæåšå°150 Baytech Drive
éœåžSAN JOSE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·95134
é»è©±çªå·16502329832
ãŠã§ããµã€ãhttps://www.procept-biorobotics.com/
äŒæ¥ã³ãŒãPRCT
äžå Žæ¥Sep 15, 2021
æé«çµå¶è²¬ä»»è
ãCEOãWood (Larry L)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã